Joshua Klopper

If your thyroid biopsy came back indeterminate — Bethesda 3 or 4 — you may have been told surgery is your only option. For decades, over 70% of those surgeries revealed tissue that was actually benign. There is a better way. It's called molecular testing. And today's guest helped prove it works. Dr. Joshua Klopper is the Medical Director for Endocrinology at Veracyte and was an investigator on the original clinical study that validated the Afirma Genomic Sequencing Classifier. He served on the board of the American Thyroid Association and spent over two decades managing thyroid nodules and thyroid cancer. Disclosure: Dr. Klopper is an employee of Veracyte, maker of the Afirma test discussed in this episode. In this episode Dr. Klopper breaks down everything a thyroid patient needs to know about molecular testing in plain language. Why the test was designed to find benign tissue rather than cancer. What a benign result actually means. Why a suspicious result doesn't automatically m…